|Table of Contents|

Research progress of diversified adjuvant therapy models for non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 03
Page:
552-556
Research Field:
Publishing date:

Info

Title:
Research progress of diversified adjuvant therapy models for non-small cell lung cancer
Author(s):
JIANG Yi; LIU Lingshuang
Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China.
Keywords:
non-small cell lung cancer; complete resection; adjuvant therapy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.03.032
Abstract:
Complete resection of stage Ⅱ-Ⅲa and Ⅲb (T3N2M0) (IASLC/UICC TNM staging,the 8th edition) non-small cell lung cancer (NSCLC) is recommended for postoperative adjuvant chemotherapy,but chemotherapy toxicity is unavoidable,and survival benefits are limited,still have a high risk of recurrence,metastasis and death.In the era of precision medicine,targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has opened a new chapter in individualized adjuvant therapy.We focus on adjuvant chemotherapy,radiotherapy,EGFR-TKI targeted therapy,anti-angiogenesis therapy,immune checkpoint inhibitors and traditional Chinese medicine treatment to review.The exploration of diversified adjuvant therapy models is expected to delay postoperative recurrence and metastasis,and maximize the survival benefits of NSCLC patients.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］GOLDSTRAW P,CHANSKY K,CROWLEY J,et al.The IASLC lung cancer staging project:proposals for revision of the TNM stage groupings in the forthcoming（eighth）edition of the TNM classification for lung cancer［J］.J Thorac Oncol,2016,11(1):39-51.
［3］中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2020 ［M］.北京:人民卫生出版社,2020:58-67. Chinese Society of Clinical Oncology Guidelines Working Committee.Guidelines of Chinese society of clinical oncology (CSCO) non-small cell lung cancer 2020 ［M］.Beijing:People's Medical Publishing House,2020:58-67.
［4］PIGON JP,TRIBODET H,SCAGLIOTTI GV,et al.Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group［J］.J Clin Oncol,2008,26(21):3552-3559.
［5］ZHONG WZ,WANG Q,MAO WM,et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-Ⅲa (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104):a randomised,open-label,phase 3 study［J］.Lancet Oncol,2018,19(1):139-148.
［6］ZHONG WZ,WANG Q,MAO WM,et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-Ⅲa (N1-N2) EGFR-mutant NSCLC:final overall survival analysis of CTONG1104 phase Ⅲ trial［J］.J Clin Oncol,2021,39(7):713-722.
［7］WU YL,TSUBOI M,HE J,et al.Osimertinib in resected EGFR-mutated non-small-cell lung cancer［J］.N Engl J Med,2020,383(18):1711-1723.
［8］朱丽华,李和根,史美育,等.非小细胞肺癌根治术后无瘤生存期影响因素分析及中药干预效果评价［J］.上海中医药杂志,2013,47(02):11-15. ZHU LH,LI HG,SHI MY,et al.Influential factors of disease free survival in radical postoperative non-small cell lung cancer and its intervention by Chinese medicine［J］.Shanghai Journal of Traditional Chinese Medicine,2013,47(02):11-15.
［9］DOUILLARD JY,TRIBODET H,AUBERT D,et al.Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer:subgroup analysis of the Lung Adjuvant Cisplatin Evaluation［J］.J Thorac Oncol,2010,5(2):220-228.
［10］BRADBURY P,SIVAJOHANATHAN D,CHAN A,et al.Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer:a systematic review［J］.Clin Lung Cancer,2017,18(3):259-273.
［11］KENMOTSU H,YAMAMOTO N,YAMANAKA T,et al.Randomized phase Ⅲ study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage Ⅱ to Ⅲa nonsquamous non-small-cell lung cancer［J］.J Clin Oncol,2020,38(19):2187-2196.
［12］BURDETT S,RYDZEWSKA L,TIERNEY JF,et al.A closer look at the effects of postoperative radiotherapy by stage and nodal status:updated results of an individual participant data meta-analysis in non-small-cell lung cancer［J］.Lung Cancer,2013,80(3):350-352.
［13］HERSKOVIC A,MAUER E,CHRISTOS P,et al.Role of postoperative radiotherapy in pathologic stage Ⅲa (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database［J］.J Thorac Oncol,2017,12(2):302-313.
［14］PATEL SH,MA Y,WERNICKE AG,et al.Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer［J］.Lung Cancer,2014,84(2):156-160.
［15］LE PECHOUX C,POUREL N,BARLESI F,et al.LBA3_PR:An international randomized trial,comparing post-operative conformal radiotherapy (PORT) to no PORT,in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement:primary end-point analysis of LungART (IFCT-0503,UK NCRI,SAKK) NCT00410683［J］.Ann Oncol,2020,31(4S):S1178.
［16］HUI ZG,MEN Y,HU C,et al.Effect of postoperative radiotherapy for patients with pⅢa-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy:the phase 3 PORT-C randomized clinical trial［J］.JAMA Oncol,2021,7(8):1178-1185.
［17］GOSS GD,O'CALLAGHAN C,LORIMER I,et al.Gefitinib versus placebo in completely resected non-small-cell lung cancer:results of the NCIC CTG BR19 study［J］.J Clin Oncol,2013,31(27):3320-3326.
［18］KELLY K,ALTORKI NK,EBERHARDT WE,et al.Adjuvant erlotinib versus placebo in patients with stage Ⅰb-Ⅲa non-small-cell lung cancer (RADIANT):a randomized,double-blind,phase Ⅲ trial［J］.J Clin Oncol,2015,33(34):4007-4014.
［19］YUE D,XU S,WANG Q,et al.Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage Ⅲa EGFR mutation-positive non-small-cell lung cancer (EVAN):a randomised,open-label,phase 2 trial［J］.Lancet Respir Med,2018,6(11):863-873.
［20］HE JX,SU CX,LIANG WH,et al.Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE):a randomised,open-label,phase 3 trial［J/OL］.Lancet Respir Med,2021:S2213-2600(21)00134-X ［2021-07-16］.https://pubmed.ncbi.nlm.nih.gov/34280355.doi:10.1016/S2213-2600(21)00134-X.
［21］SANDLER A,GRAY R,PERRY MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer［J］.N Engl J Med,2006,355(24):2542-2550.
［22］ZHOU C,WU YL,CHEN G,et al.BEYOND:A randomized,double-blind,placebo-controlled,multicenter,phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer［J］.J Clin Oncol,2015,33(19):2197-2204.
［23］WAKELEE HA,DAHLBERG SE,KELLER SM,et al.Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505):an open-label,multicentre,randomised,phase 3 trial［J］.Lancet Oncol,2017,18(12):1610-1623.
［24］PIRKER R,FILIPITS M.Adjuvant therapy in patients with completely resected non-small-cell lung cancer:current status and perspectives［J］.Clin Lung Cancer,2019,20(1):1-6.
［25］MIELGO-RUBIO X,CALVO V,LUNA J,et al.Immunotherapy moves to the early-stage setting in non-small cell lung cancer:emerging evidence and the role of biomarkers［J］.Cancers (Basel),2020,12(11):3459.
［26］刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察［J］.上海中医药杂志,2001,35(2):4-6. LIU JX,SHI ZM,LI HG,et al.Clinical observation of "lung-nourishing anti-tumor beverage" in treating non-small-cell lung cancer in 271 cases［J］.Shanghai Journal of Traditional Chinese Medicine,2001,35(2):4-6.
［27］刘苓霜,张朋,姜怡,等.中医扶正法治疗肺癌的临床疗效及其对机体的免疫调节作用［J］.自然杂志,2019,41(4):281-286. LIU LS,ZHANG P,JIANG Y,et al.Clinical efficacy of traditional Chinese medicine with strengthening healthy energy on lung cancer and its immunomodulatory effect on the body［J］.Chinese Journal of Nature,2019,41(4):281-286.
［28］WANG Q,JIAO L,WANG S,et al.Adjuvant chemotherapy with Chinese herbal medicine formulas versus placebo in patients with lung adenocarcinoma after radical surgery:a multicenter,randomized,double-blind,placebo-controlled trial［J］.Biol Proced Online,2020,22:5.
［29］顾琳萍,叶翔贇,徐云华,等.中医药联合辅助化疗治疗早期非小细胞肺癌的随机双盲对照临床研究［J］.肿瘤研究与临床,2016,28(06):394-398,403. GU LP,YE XY,XU YH,et al.A double-blind and randomized controlled clinical trial of traditional Chinese medicine combined with adjuvant chemotherapy for early stage non-small cell lung cancer［J］.Cancer Research and Clinic,2016,28(06):394-398,403.
［30］侯宛昕,李和根,陈智伟,等.中医药联合辅助化疗治疗完全性切除非小细胞肺癌的临床研究［J］.中国中西医结合杂志,2015,35(6):648-653. HOU WX,LI HG,CHEN ZW,et al.Treatment of radical resected NSCLC by Chinese medicine combined with adjuvant chemotherapy:a Clinical study［J］.Chinese Journal of Integrated Traditional and Western Medicine,2015,35(6):648-653.
［31］王中奇,徐振晔,邓海滨,等.中医药结合化疗防治非小细胞肺癌术后复发转移的临床研究［J］.上海中医药杂志,2011,45(05):36-39. WANG ZQ,XU ZY,DENG HB,et al.Clinical research on Chinese medicine combined with chemotherapy in preventing tumor metastasis and recurrence in postoperative non-small cell lung cancer［J］.Shanghai Journal of Traditional Chinese Medicine,2011,45(05):36-39.
［32］辛晓丽,姜怡,沈丽萍,等.中医药辅助治疗600例老年非小细胞肺癌患者的生存分析［J］.中医杂志,2019,60(01):31-35,46. XIN XL,JIANG Y,SHEN LP,et al.Survival analysis of 600 elderly patients with non-small cell lung cancer treated with traditional Chinese medicine［J］.Journal of Traditional Chinese Medicine,2019,60(01):31-35,46.
［33］ZHANG SF,CHEN WQ,WANG YL,et al.Chinese herbal prescription fu-zheng-qu-xie prevents recurrence and metastasis of postoperative early-stage lung adenocarcinoma:a prospective cohort study followed with potential mechanism exploration［J］.Oxid Med Cell Longev,2021,2021:6673828.

Memo

Memo:
上海市卫生和计划生育委员会面上项目（编号：201840158）；上海申康医院发展中心新兴前沿技术联合攻关项目（编号：SHDC12018124）；上海市科学技术委员会科研项目（编号：19401971200）；刘嘉湘国医大师传承工作室建设项目（编号：DSGZS-2017002）
Last Update: 1900-01-01